Sally Bryan is co-chair of the Product Liability and Mass Torts Practice Group.  Her practice primarily consists of litigation in the setting of the pharmaceutical industry, but also involves the litigation of matters in other commercial settings.

In the pharmaceutical setting, Ms. Bryan has, for almost fifteen years, been part of multiple regional and national representations involving both vaccines and drug products.  In this capacity, she has had direct or supervisory responsibility for a wide variety of activities ranging from interacting extensively with company witnesses in connection with the factual development of the company cases of her clients, to the design and use of databases for the management, analysis, and production of documents in matters of all sizes, to the supervision and management of the collection, review, and production of both hard copy and electronic documents in matters of varying sizes, to the oversight of third-party vendors and dozens of attorneys and paralegals working in a number of different capacities.  In recent years, Ms. Bryan has provided similar services to clients in other commercial settings, including those responsible for conducting medical research and those in the healthcare and defense industries.

Representative Matters

• The representation of a vaccine manufacturer in a nationwide litigation involving the allegation that a preservative in vaccines causes autism.
• The representation of the manufacturer of a cholesterol-reducing drug in a nationwide litigation where plaintiffs claimed that the drug caused the development of muscle and psychological injuries.
• The representation of a manufacturer in connection with several congressional inquiries.
• The representation of the manufacturer of an antiepileptic drug in a nationwide litigation involving allegations of birth defect injuries.
• The representation of the manufacturer of a pain medication in a nationwide litigation involving allegations that the drug caused the development of chondrolysis.
• The representation of the manufacturer in a nationwide litigation where plaintiffs claimed that an injectable drug used to control nausea and vomiting led to the development of tardive dyskinesia.
• The representation of a manufacturer in connection with claims of research fraud.

• The representation of a prominent medical research institution and researcher in a case involving a claim of research fraud.
• The representation of an information security company in a case involving a dispute over the use of encryption technology.
• The representation of a regional healthcare system in a case involving a breach of contract claim related to the supply of drugs to hospitals.
• The representation of a leading advanced materials company in connection with its use of cadmium in enamels.